Vivoryon Therapeutics N.V. · EURONEXT:VVY

Vivoryon Therapeutics — Investor Presentation (January 2023)

17 slides from Vivoryon Therapeutics's investor presentation, January 2023

  1. Slide 1: Tackling AD at the roots: early intervention to address multiple hallmarks of AD

    Tackling AD at the roots: early intervention to address multiple hallmarks of AD |Vivoryon Therapeutics N.V. – January 2023

  2. Slide 2: Important Notice and Disclaimer

    IMPORTANT NOTICE AND DISCLAIMER IMPORTANT: YOU MUST READ THE BELOW BEFORE READING THIS DOCUMENT This document has been prepared by Vivoryon Therapeutics N.V. (the “Company” or “We”) strictly only for discussion purposes. This document does not constitute or form part of any offer or invitation to se

  3. Slide 3: Investment Highlights

    VIVORYON THERAPEUTICS Investment Highlights LATE-STAGE LEAD PROGRAM VAROGLUTAMSTAT APPROACH ◆ DIFFERENTIATED UPSTREAM APPROACH TO ALZHEIMER’S DISEASE treatment targeting major hallmarks of disease with ◆ PURPOSE-BUILT PIPELINE of small proven early signs of disease-modifying molecules addressing med

  4. Slide 4: Experienced Leadership

    EXPERIENCED LEADERSHIP Seasoned Biopharma Experts Covering All Relevant Aspects of Drug Development EXECUTIVE DIRECTORS NON-EXECUTIVE DIRECTORS Ulrich Dauer, PhD Erich Platzer, MD Chief Executive Officer, Executive Director Chairman Dinnies Johannes von der Osten, PhD Vice Chairman Charlotte Lohmann

  5. Slide 5: Diverse Pipeline Addressing Severe Diseases

    DIVERSE PIPELINE ADDRESSING SEVERE DISEASES Program Approach Discovery Preclinical Phase 1 Phase 2a Phase 2b Phase 3 Varoglutamstat SMI (PQ912) QPCT/L VIVIAD - Ph2b in EU Varoglutamstat SMI (PQ912) QPCT/L VIVA-MIND - Ph2a/b in US Varoglutamstat SMI AD (SIM0408, PQ912) QPCT/L CTA approval in China mA

  6. Slide 6: Alzheimer's Disease: The Burden and a Path Forward

    ALZHEIMER’S DISEASE THE BURDEN A PATH FORWARD ~30 million people suffering from AD VVY discovered QPCT-mediated formation of a neurotoxic Abeta variant, worldwide, number expected to double by N3pE amyloid (pGlu-Abeta), as driver of AD pathology1,2 2050, with ~12.7 million in the US alone VVY is dev

  7. Slide 7: Drug Development in Alzheimer's Disease

    DRUG DEVELOPMENT IN ALZHEIMER’S DISEASE THE CHALLENGE Low success rate and long development phase delay new treatments and discourage investment in AD drug development Studies across drug development programs have identified important strategies for decreasing the risk and increasing the likelihood

  8. Slide 8: Lead Product Candidate: Varoglutamstat

    LEAD PRODUCT CANDIDATE: VAROGLUTAMSTAT PREVENTS N3pE-FORMATION IN AD ROLE OF QPCT/L IN AD PATHOLOGY VAROGLUTAMSTAT TARGETS UPSTREAM PATHOGENESIS Increased activity of glutaminyl cyclase (QPCT) is CCL2 Abeta associated with AD pathology in humans1 upregulated in AD Varoglutamstat QPCT catalyzes forma

  9. Slide 9: Translating In Vivo Evidence for Relevance of QPCT/L Inhibition into Human AD

    TRANSLATING IN VIVO EVIDENCE FOR RELEVANCE OF QPCT/L INHIBITION INTO HUMAN AD Abeta Pathology QPCT is essential for N3pE amyloid formation in vivo1 Dose-dependent reduction of QPCT 5XFAD mice, QPCT ko and tg QPCT/ N3pE activity in CSF & serum (Ph1 + Ph2a) Neuroinflammation CCL2 activity promotes Tau

  10. Slide 10: Varoglutamstat Clinical Development Strategy

    VAROGLUTAMSTAT CLINICAL DEVELOPMENT STRATEGY Clear Path To Potential Regulatory Approval Based on Well-Informed Trials Extensive Phase 1 and Phase 2 Trials Pivotal study or Phase 2b VIVIAD accelerated approval Assessment of safety, tolerability and FDA Fast Track designation efficacy in 250 patients

  11. Slide 11: Summary of Key Phase 2a Results

    SAPHIR– GUIDING PHASE 2B TRIAL DESIGN COGNITION INFORMED TRIAL DESIGN OF EU PHASE 2B Statistically significant changes from baseline in a SUMMARY OF KEY PHASE 2A RESULTS working memory parameter within 3 months (One Back DOSING Test) CCL2 DLT reached at 800 mg BID; reported AEs mostly mild to Notabl

  12. Slide 12: Multiple Avenues to Value Generation

    MULTIPLE AVENUES TO VALUE GENERATION Diverse Pipeline of Oral Small Molecule Inhibitors to Address Exceptionally High Medical Need ALZHEIMER‘S DISEASE INFLAMMATION/NASH Small molecule oral QPCT/L inhibitors with good Small molecule QPCTL inhibitors to modulate the blood-brain barrier penetration CCL

  13. Slide 13: QPCTL Inhibition in Cancer

    QPCTL INHIBITION IN CANCER Opportunity to Develop Oral Small Molecule Inhibitors in Immuno-Oncology BACKGROUND OPPORTUNITY Large unmet medical need remains to effectively and safely treat cancer Novel orally administered small molecule approach with differentiated mode patients of action: no antigen

  14. Slide 14: QPCTL Inhibition in Inflammation/NASH

    QPCTL INHIBITION IN INFLAMMATION/NASH Opportunity to Develop Oral Small Molecule Inhibitors in Inflammatory Kidney and Liver Diseases BACKGROUND OPPORTUNITY Non-alcoholic fatty liver disease (NAFLD) is a chronic hepatic Novel orally available compounds with a differentiated mode of disorder characte

  15. Slide 15: Meprin Inhibition in AKI/CKD

    MEPRIN INHIBITION IN AKI/CKD Opportunity to Develop Oral Small Molecule Inhibitors In Fibrosis and Kidney Diseases BACKGROUND OPPORTUNITY The estimated incidence rate of acute kidney injury (AKI) during Novel orally available picomolar small molecule inhibitors targeting hospitalization in the US is

  16. Slide 16: Positioned for Continued Value Generation

    POSITIONED FOR CONTINUED VALUE GENERATION PRESENT FOCUS FUTURE OPPORTUNITIES UPCOMING CATALYSTS Differentiated upstream Regional partnership with approach targeting all three Simcere: VIVIAD European Phase 2b: major hallmarks of AD Development opportunities for Final readout Q1/2024 Allows intervent

  17. Slide 17: Vivoryon Therapeutics N.V. Contact

    Vivoryon Therapeutics N.V. Halle (Saale) Weinbergweg 22 06120 Halle (Saale) Germany Munich Franz-Josef-Delonge-Str. 5 81249 München Germany [email protected] +49 (0)345 555 99 00 www.vivoryon.com

Vivoryon Therapeutics — Investor Presentation (January 2023) on 6ix